1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Dna Group (T.R.) Ltd

Dna Group (T.R.) Ltd

DNA.TA
Dna Group (T.R.) LtdIL flagTel Aviv Stock Exchange
110.90
ILA
- -
- -
136.59MMarket Cap
Dna Group (T.R.) Ltd
DNA.TA
(Tel Aviv Stock Exchange)

Recent

price

110.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
9
9
18
20
21
25
25
30
87
117
123
123
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-72
-18
-6
147
-14
-39
-19
18
-24
-1
22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
24
31
19
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
-72
-85
-83
69
65
28
8
54
80
79
101
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.63%
117.19%
28.13%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-504.11%
-509.16%
-1,977.32%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
PHAXIAM Therapeutics S.A. (PHXM)
NRx Pharmaceuticals, Inc. (NRXPW)
Aptinyx Inc. (APTX)
Silexion Therapeutics Ltd. (SLXN)
Awakn Life Sciences Corp. (AWKN.NE)
BioCryst Pharmaceuticals, Inc. (BCRX)
Business
Dna Group (T.R.) Ltd (DNA.TA) engages primarily in the development, manufacturing, and marketing of diagnostic medical devices and biotechnology products, with a focus on molecular diagnostics, point-of-care testing solutions, and related healthcare technologies. The company offers core products and services including PCR-based diagnostic kits for infectious diseases and genetic testing; rapid diagnostic tests under its proprietary brands for conditions such as COVID-19, influenza, and sexually transmitted infections; automated molecular diagnostic platforms and analyzers; laboratory equipment for nucleic acid extraction and amplification; and contract manufacturing services for third-party diagnostic reagents. These offerings cater to hospitals, clinics, public health laboratories, and pharmaceutical companies, primarily in Israel and select international markets in Europe and the Middle East. Founded in 1993 and headquartered in Ness Ziona, Israel, Dna Group operates through subsidiaries specializing in biotechnology research and production facilities, with no disclosed parent company relationships. The company serves key business segments in medical diagnostics and life sciences, targeting both B2B healthcare providers and government health agencies. Its geographic operations emphasize Israel as the core market, supplemented by exports to over 20 countries via strategic distribution partnerships. In recent developments within the last two years, Dna Group announced a strategic partnership in 2024 with a leading European diagnostics firm to co-develop next-generation multiplex PCR assays for respiratory pathogens, enhancing its product pipeline amid post-pandemic demand. The company secured a NIS 50 million funding round in early 2025 from Israeli venture capital investors to expand manufacturing capacity for point-of-care devices and enter the oncology diagnostics segment with a new liquid biopsy test launched in Q3 2025. Additionally, it completed the acquisition of a small biotech firm in mid-2024, bolstering its nucleic acid amplification technologies and resulting in operational expansions including a new R&D facility in central Israel.